Du Pont-Sankyo Pharmaceuticals Company Limited Company Profile

19:00 EDT 21st September 2017 | BioPortfolio



Daini Kowa Building 11-39 Akasaka 1-chome Minato-ku


Phone: 81 3 3585 4050
Fax: 81 3 3587 0336

News Articles [2705 Associated News Articles listed on BioPortfolio]

Daiichi Sankyo, Boston Pharmaceuticals sign deal for selective RET inhibitor for solid tumors

Daiichi Sankyo and Boston Pharmaceuticals have entered into a worldwide licensing agreement for Daiichi Sankyo's novel RET inhibitor, DS-5010.

FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo’s DS-8201 for HER2-Positive Metastatic Breast Cancer

Tokyo, Japan, Basking Ridge, NJ, and Munich, Germany – (August 29, 2017) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the U.S. Food and Drug Administration (F...

Daiichi Sankyo Q1 Profit Down; Sees Higher Profit, Lower Sales In FY

TOKYO (dpa-AFX) - Japanese pharmaceuticals company Daiichi Sankyo Co. Ltd. (DSKYF.PK) reported Monday that its first-quarter profit attributable to owners of the company declined 4.7 percent to 29...

Daiichi Sankyo and MD Anderson Collaborate to Accelerate Development of Acute Myeloid Leukemia Therapies

HOUSTON and TOKYO and BASKING RIDGE, N.J., Sept. 14, 2017 /PRNewswire/ — The University of Texas MD Anderson Cancer Center and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today a...

Daiichi Sankyo, SBP begin phase 1 trial of DS─1211 in hyealthy volunteers

Daiichi Sankyo Company, Limited and Sanford Burnham Prebys Medical Discovery Institute (SBP) announced the start of a phase 1, first─in─human clinical trial of DS─1211 in healthy volunteers. DS...

Du Pont: Aktie mit Ausbruch und Kaufsignal

Am Freitag erfolgte bei dem Wertpapier von Du Pont Nemours ein Kursanstieg über eine äußerst markante Hürde aus den letzten Monaten - der schwächere Montagshandel weckte zeitweise aber noch leich...

Daiichi Sankyo begins phase 3 ENVISAGE─TAVI AF study of once─daily Lixiana to treat patients with AF undergoing TAVI

Daiichi Sankyo Company, Limited, announced that the first patient has been enrolled into the ENVISAGE─TAVI AF study. The multinational, randomized phase 3b study will evaluate a treatment regimen ba...

Zymeworks and Daiichi Sankyo Announce Successful Achievement of a Research Milestone in ...

Zymeworks:David Poon, Ph.D.Executive Director, External R&D and Alliances(604) 678-1388bd@zymeworks.comorInvestor Inquiries:David MatousekSenior Manager, Investor Relations & ...

Drugs and Medications [1579 Associated Drugs and Medications listed on BioPortfolio]



Drug Facts


Famotidine Tablets, USP 20 mg

Benicar [Daiichi Sankyo, Inc]

These highlights do not include all the information needed to use Benicar safely and effectively. See full prescribing information for Benicar. Benicar (olmesartan medoxomil) tablets Initial U.S. Appr...



PubMed Articles [182 Associated PubMed Articles listed on BioPortfolio]

Announcing the 2017 Pharmaceuticals Travel Award for Young Post-Doctoral Researchers.

Last year, for the first time in its history, our Journal was able to offer a travel grant of 800 CHF to a young researcher in the field of medicinal chemistry.

Suspended solids moderate the degradation and sorption of waste water-derived pharmaceuticals in estuarine waters.

This study focuses on the fate of pharmaceuticals discharged into an estuarine environment, particularly into the Turbidity Maximum Zone (TMZ). Batch experiments were set up to investigate the factors...

Chiral pharmaceuticals: A review on their environmental occurrence and fate processes.

More than 50% of pharmaceuticals in current use are chiral compounds. Enantiomers of the same pharmaceutical have identical physicochemical properties, but may exhibit differences in pharmacokinetics,...

Comparative study on pharmaceuticals adsorption in reclaimed water desalination concentrate using biochar: Impact of salts and organic matter.

The synergistic impact of salts and organic matter on adsorption of ibuprofen and sulfamethoxazole by three types of biochar and an activated carbon was investigated using reclaimed water reverse osmo...

Estimation of amount of selected pharmaceuticals sorbed onto digested sludge from wastewater treatment plant Bratislava-Petržalka.

Antibiotics and antidepressants are among the most successful drugs used for human therapy. Their concentration in influent on WWTP is relative high and there can be removed by biodegradation or sorpt...

Clinical Trials [266 Associated Clinical Trials listed on BioPortfolio]

BE Study of Torrent's Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Tab - Fed Conditions

Subjects to compare the single dose bioavailability of Torrent's Olmesartan medoxomil, Amlodipine and Hydrochlorothiazide Tablets 40+10+25 mg and Tribenzor® 40+10+25 mg Tablets of Daichi ...

Bioequivalence Study of Torrent's Olmesartan Medoxomil, Amlodipine and Hydrochloride Tablets Under Fasting Conditions.

Subjects to compare the single dose bioavailability of Torrent's Olmesartan medoxomil, Amlodipine and Hydrochlorothiazide Tablets 40+10+25 mg and Tribenzor® 40+10+25 mg Tablets of Daichi ...

Epidemiology of Cardiovascular and Non-Cardiovascular Risk In Chicago

To continue the comprehensive research program on the epidemiology of cardiovascular and other major chronic diseases, including cancer and diabetes, in four Chicago population cohorts. T...

Comparative Study of Loxoprofen Sodium Transdermal Patch and Loxonin® Tablets for the Treatment of Acute Trauma

This study evaluates the non-inferiority of the new transdermal patch dosage form containing loxoprofen sodium (100 mg - Daiichi-Sankyo) in comparison with oral Loxonin® (60 mg tablet - D...

Buspirone Hydrochloride 30mg Tablets, Fasting

This study will compare the relative bioavailability (rate and extent of absorption) of 30 mg Buspirone Hydrochloride Tablets by TEVA Pharmaceuticals Industries, Ltd. with that of 30 mg BU...

Companies [2759 Associated Companies listed on BioPortfolio]

Du Pont-Sankyo Pharmaceuticals Company Limited


Sankyo Co., Ltd.

Since Sankyo's founding, the Company has been continuously motivated by an unstinting drive to bring new pharmaceuticals to market. This introduction to Sankyo's progress to date will reveal the eager...

Daiichi Sankyo

The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. ...

Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited, established in 2005 after the joint share transfer of two leading century-old Japanese pharmaceutical companies, is continuously generating innovative drugs that e...


DAIICHI SANKYO is a global pharmaceutical company that focuses on researching and marketing innovative medications. The company was created in 2005 through the merger of two traditional Japanese e...

More Information about "Du Pont-Sankyo Pharmaceuticals Company Limited" on BioPortfolio

We have published hundreds of Du Pont-Sankyo Pharmaceuticals Company Limited news stories on BioPortfolio along with dozens of Du Pont-Sankyo Pharmaceuticals Company Limited Clinical Trials and PubMed Articles about Du Pont-Sankyo Pharmaceuticals Company Limited for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Du Pont-Sankyo Pharmaceuticals Company Limited Companies in our database. You can also find out about relevant Du Pont-Sankyo Pharmaceuticals Company Limited Drugs and Medications on this site too.

Quick Search

Corporate Database Quicklinks

Searches Linking to this Company Record